Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Teduglutide recombinant
Drug ID BADD_D02138
Description Teduglutide is a glucagon-like peptide-2 (GLP-2) analogue. It is made up of 33 amino acids and is manufactured using a strain of Escherichia coli modified by recombinant DNA technology. Teduglutide differs from GLP-2 by one amino acid (alanine is substituted by glycine). The significance of this substitution is that teduglutide is longer acting than endogenous GLP-2 as it is more resistant to proteolysis from dipeptidyl peptidase-4. FDA approved on December 21, 2012.
Indications and Usage Treatment of short bowel syndrome (SBS), malabsorption associated with the removal of the intestine, in adults patients who are dependent on parenteral support.
Marketing Status approved
ATC Code A16AX08
DrugBank ID DB08900
KEGG ID D06053
MeSH ID C494910
PubChem ID 70683012
TTD Drug ID D00RCI
NDC Product Code 63557-1031; 68225-087; 68875-0101; 68875-0102; 69766-106; 68594-001; 41524-0009; 68875-0103; 17337-0264
UNII Not Available
Synonyms teduglutide | Gly(2)-GLP-2 | (Gly2)GLP-2
Chemical Information
Molecular Formula C164H252N44O55S
CAS Registry Number 197922-42-2
SMILES CCC(C)C(C(=O)NC(C(C)O)C(=O)NC(CC(=O)O)C(=O)O)NC(=O)C(CCCCN)NC(=O)C(C(C)O)NC(=O)C (CCC(=O)N)NC(=O)C(C(C)CC)NC(=O)C(CC(C)C)NC(=O)C(CC1=CNC2=CC=CC=C21)NC(=O)C(CC(=O )N)NC(=O)C(C(C)CC)NC(=O)C(CC3=CC=CC=C3)NC(=O)C(CC(=O)O)NC(=O)C(CCCNC(=N)N)NC(=O) C(C)NC(=O)C(C)NC(=O)C(CC(C)C)NC(=O)C(CC(=O)N)NC(=O)C(CC(=O)O)NC(=O)C(CC(C)C)NC(= O)C(C(C)CC)NC(=O)C(C(C)O)NC(=O)C(CC(=O)N)NC(=O)C(CCSC)NC(=O)C(CCC(=O)O)NC(=O)C(C C(=O)O)NC(=O)C(CO)NC(=O)C(CC4=CC=CC=C4)NC(=O)C(CO)NC(=O)CNC(=O)C(CC(=O)O)NC(=O)C NC(=O)C(CC5=CNC=N5)N
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal pain07.01.05.002--
Anxiety19.06.02.002--
Arthralgia15.01.02.001--
C-reactive protein increased13.09.01.007---
Cardiac failure congestive02.05.01.002---
Chest pain02.02.02.011; 08.01.08.002; 22.12.02.003---
Cholecystitis09.03.01.001--
Cholestasis09.01.01.001---
Cough22.02.03.001--
Dermatitis atopic10.01.04.004; 23.03.04.016---
Dizziness02.11.04.006; 17.02.05.003; 24.06.02.007--
Dyspnoea02.11.05.003; 22.02.01.004--
Flushing08.01.03.025; 23.06.05.003; 24.03.01.002--
Gastrointestinal disorder07.11.01.001---
Gastrointestinal pain07.01.05.005--
Headache17.14.01.001--
Infection11.01.08.002---
Influenza11.05.03.001; 22.07.02.001---
Injection site erythema08.02.03.001; 12.07.03.001; 23.03.06.015---
Injection site haematoma08.02.03.004; 12.07.03.004; 24.07.01.009---
Injection site pain08.02.03.010; 12.07.03.011---
Injection site reaction08.02.03.014; 12.07.03.015--
Intestinal obstruction07.13.01.002---
Loss of consciousness17.02.04.004---
Nausea07.01.07.001--
Nervous system disorder17.02.10.001---
Night sweats08.01.03.031; 23.02.03.006---
Oedema peripheral02.05.04.007; 08.01.07.007; 14.05.06.011--
Pancreatitis07.18.01.001--
Paraesthesia17.02.06.005; 23.03.03.094--
The 1th Page    1 2    Next   Last    Total 2 Pages